Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells

Blood

Volumn 95, Issue 4, 2000, Pages 1342-1349

  Osterroth, Frank ^b   Garbe, Annette ^b   Fisch, Paul ^b   Veelken, Hendrik ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CD8 ANTIGEN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN IDIOTYPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; VIRUS VECTOR;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LYMPHOMA; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MALE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0034651722     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.4.1342.004k19_1342_1349     Document Type: Article

References (43)

1. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol. 1997;9:10.
2. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245.
3. Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med. 1995; 182:389.
4. Lanzavecchia A. Mechanisms of antigen uptake for presentation. Curr Opin Immunol. 1998;8:348.
5. Rock KL. A new foreign policy: MHC class I molecules monitor the outside world. Immunol Today. 1996;17:131.
6. Chaux P, Vantomme V, Coulie P, Boon T, van der Bruggen P. Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer. Int J Cancer. 1998;77:538.
7. Staveley-O'Carroll K, Sotomayor E, Montgomery J, et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci U S A. 1998;95:1178.
8. Fields P, Fitch FW, Gajewski TF. Control of T lymphocyte signal transduction through clonal anergy. J Mol Med. 1996;74:673.
9. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte-macrophage colony-stimulating factor plus interleukin-4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994;179:1109.
10. Herbst B, Köhler G, Mackensen A, Veelken H, Mertelsmann R, Lindemann A. CD34+ peripheral blood progenitor cell-and monocyte-derived dendritic cells: a comparative analysis. Br J Haematol. 1997;99:490.
11. Mackensen A, Herbst B, Köhler G, et al. Delineation of the dendritic cell lineage by generating large numbers of Birbeck granule-positive Langerhans cells from human peripheral blood progenitor cells in vitro. Blood. 1995;86:2699.
12. Fisch P, Köhler G, Garbe A, et al. Generation of antigen-presenting cells for soluble protein antigens ex vivo from peripheral blood progenitor cells in cancer patients. Eur J Immunol. 1996;26: 595.
13. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996; 2:52.
14. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328.
15. Mackensen A, Carcelain G, Viel S, et al. Direct evidence to support the immunosurveillance concept in a human regressive melanoma. J Clin Invest. 1994;93:1397.
16. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med. 1996;183:725.
17. Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B cell lymphoma with monoclonal antiidiotype antibody. N Engl J Med. 1982;306:517.
18. Luna-Fineman S, Lee JE, Wesley PK, Clayberger C, Krensky AM. Human cytotoxic T-lymphocytes specific for autologous follicular lymphoma cells recognize immunoglobulin in a major histocompatibility complex restricted fashion. Cancer. 1992;70:2181.
19. Schultze J, Seamon MJ, Michalak S, Gribben JG, Nadler LM, Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. Blood. 1997;89:3806.
20. Nelson EL, Li X, Hsu FJ, et al. Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. Blood. 1996;88:580.
21. Hsu FJ, Caspar CB, Czerwinski D, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma: long-term results of a clinical trial. Blood. 1997;89:3129.
22. Österborg A, Yi Q, Henriksson L, et al. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8-and CD4-specific T-cell responses. Blood. 1998;91:2459.
23. Kwak LW, Young HA, Pennington RW, Weeks SD. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/ macrophage colony-stimulating factor primes mice for a protective T cell response. Proc Natl Acad Sci U S A. 1996;93:10,972.
24. Levitsky HI, Montgomery J, Ahmadzadeh M, et al. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent antitumor immunity. J Immunol. 1996;156:3858.
25. King CA, Spellerberg MB, Zhu D, et al. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med. 1998;4:1281.
26. Syrengelas AD, Levy R. DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection. J Immunol. 1999;162: 4790.
27. Osterroth F, Alkan O, Mackensen A, et al. Rapid expression cloning of human immunoglobulin Fab fragments for the analysis of antigen specificity of B cell lymphomas and anti-idiotype lymphoma vaccination. J Immunol Methods. 1999; 229:141.
28. Skerra A. A general vector, pASK84, for cloning, bacterial production, and single-step purification of antibody Fab fragments. Gene. 1994;141:79.
29. Skerra A. Use of the tetracycline promoter for the tightly regulated production of a murine antibody fragment in Escherichia coli. Gene. 1994;151: 131.
30. Liljeström P, Garoff H. A new generation of animal cell expression vectors based on the Semliki Forest Virus replicon. Bio/Technology. 1991;9:1356.
31. Gajewski TF Renauld JC, van Pel A, Boon T. Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro. J Immunol. 1995;154: 5637.
32. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol. 1994;152:163.
33. Carroll WL, Thielemans K, Dilley J, Levy R. Mouse × human heterohybridomas as fusion partners with human B cell tumors. J Immunol Methods. 1986;89:61.
34. McCormick AA, Kumagai MH, Hanley K, et al. Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants. Proc Natl Acad Sci U S A. 1999;96:703.
35. Wen YJ, Lim SH. T cells recognize the VH complementarity-determining region 3 of the idiotypic protein of B cell non-Hodgkin's lymphoma. Eur J Immunol. 1997;27:1043.
36. Zhou X, Berglund P, Zhao H, Liljestrom P, Jondal M. Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest Virus. Proc Natl Acad Sci U S A. 1995;92: 3009.
37. Kovacsovics-Bankowski M, Rock KL. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I moleculues. Science. 1995;267:243.
38. Zitvogel L, Mayordomo JI, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper 1-associated cytokines. J Exp Med. 1996;183:87.
39. Sigal LJ, Crotty S, Andino R, Rock KL. Cytotoxic T-cell immunity to virus-infected non-hematopoetic cells requires presentation of exogenous antigen. Nature. 1999;398:77.
40. Fernandez NC, Lozier A, Flament C, et al. Dendritic cells directly trigger NK cell functions: crosstalk relevant in innate anti-tumor immune responses in vivo. Nat Med. 1999;5:405.
41. Bertz H, Burger JA, Kunzmann R, Mertelsmann R, Finke J. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect. Leukemia. 1997;11:281.
42. Kwak LW, Taub DD, Duffey PL, et al. Transfer of myeloma idiotype-specific immunity from an actively immunized marrow donor. Lancet. 1995; 345:1016.
43. Kwak LW, Pennington R, Longo DL. Active immunization of murine allogeneic bone marrow transplant donors with B-cell tumor-derived idiotype: a strategy for enhancing the specific antitumor effect of marrow grafts. Blood. 1996;87:3053.